Searchable abstracts of presentations at key conferences in endocrinology

ea0072p11 | (1) | UKINETS2020

The discontinuation of interferon-alfa for the treatment of metastatic NET: A case amongst many of poorer patient outcomes?

Fenn Ricky , Pawsey Alexander , Kapur Gaurav

Interferon alfa-2a was discontinued in June 2020. Here we present a case of an unfortunate patient for whom this change has dramatically impacted the course of her illness. A 64-year-old woman initially presented in 2007 with refractory hypertension and was found to have a phaeochromocytoma which was resected. Metastatic recurrence of her disease in the liver and vertebrae was confirmed by CT/MRI in 2014 following rising catecholamines on monitoring. Her MIBG scan in early 201...